{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG|Positive|Treatment of Gaucher disease" in comments (approximate match)
Showing 1 - 3 of 3 results
Status:
US Approved Rx
(2012)
Source:
BLA022458
(2012)
Source URL:
First approved in 2012
Source:
BLA022458
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
Source:
BLA022575
(2010)
Source URL:
First approved in 2010
Source:
BLA022575
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2014)
Source:
NDA205494
(2014)
Source URL:
First approved in 2014
Source:
NDA205494
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eliglustat, marketed by Genzyme as CERDELGA, is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers (PMs) as detected by an FDA-cleared test.
